Ireland Pharmaceuticals & Healthcare Report

Published 08 June 2015

  • 89 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
$1,295.00
Ireland Pharmaceuticals & Healthcare Report

BMI View: In line with our long-standing view, merger and acquisition activity targeting Irish pharmaceutical firms has remained intense in H115, while this trend is expected to continue over a multi-quarter horizon a gainst a backdrop of strong fundamentals and Ireland's government policies to attract foreign investment in the pharmaceutical sector . R ecent acquisitive trends are illustrated by ongoing merger bids between Mylan, Perrigo and Teva, as well as Actavis ' acquisition of Allergan, of which the outcome will likely reshape the global generic industry. Meanwhile, strong recovery of the Irish economy, diminishing unemployment and rising consumption pose upsi de risks to our pharmaceutical and healthcare sector forecasts.

Headline Expenditure Projections

  • Pharmaceuticals: EUR2.39bn (USD3.20bn) in 2014 to EUR2.35bn (USD2.58bn) in 2015; -1.7% in local currency terms and -19.3% in US dollar terms. Forecast revised upwards from last quarter.

  • Healthcare: EUR14.75bn (USD19.76bn) in 2014 to EUR14.88bn (USD16.37bn) in 2015; 0.9% in local currency terms and -17.2% in US dollar terms. Forecast revised upwards from last quarter.

Risk/Reward Index

In Q315, Ireland's Risk Reward Index score remains at 58.7 out of 100, ranking it 14 out of 15 countries in Western Europe in terms of attractiveness to pharmaceutical investors. Ireland's score is driven by high spending per capita on medicine (spending per capita score 8.4 out of 12) and low industry and country risks (patent respect score 6.3 out of 7 and business transparency score 1.9 out of 2), but dragged down by a small market size (market expenditure score 10 out of 20) and weak dynamism (sector value growth score 0.0 out of 20).

Key Trends And Developments

May 2015

  • US-based pharmaceutical company Alexion will build a EUR450mn (USD507mn) biologics manufacturing facility in Blanchardstown, Dublin, the firm's first biofacility outside the US. The facility will support the production and...

BMI Industry View
7
SWOT
10
Political
12
Economic
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Ireland 2011-2019)
16
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Ireland 2011-2019)
20
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Ireland 2011-2019)
20
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Ireland 2011-2019)
20
Prescription Drug Market Forecast
21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Ireland 2011-2019)
23
OTC Medicine Market Forecast
24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Ireland 2011-2019)
25
Pharmaceutical Trade Forecast
26
Table: Top 15 Pharmaceuticals and Healthcare Export Companies In 2013
28
Table: Pharmaceutical Trade Data And Forecasts (Ireland 2013-2019)
29
Table: Pharmaceutical Trade Data And Forecasts local currency (Ireland 2013-2019)
29
Key Risks To BMI's Forecast Scenario
30
Macroeconomic Forecasts
31
Economic Analysis
31
Table: Economic Activity (Ireland 2010-2019)
36
Industry Risk Reward Index
37
Western Europe Risk/Reward Index
37
Ireland Risk/Reward Index
41
Rewards
42
Risks
42
Market Overview
44
Industry Trends And Developments
45
Epidemiology
45
Healthcare Sector
46
Health Insurance
48
Table: Health Status
50
Table: Healthcare Funding
50
Table: Healthcare Resources (Ireland 2009-2014)
51
Table: Healthcare Personnel (Ireland 2009-2014)
51
Table: Healthcare Activity (Ireland 2009-2014)
52
Research And Development
52
Clinical Trials
53
Regulatory Development
55
Pricing Regime
59
Reimbursement Regime
62
Competitive Landscape
65
Research-Based Industry
65
Table: Pharmaceutical Companies In Ireland
73
Generic Drugmakers
74
Pharmaceutical Distribution
75
Demographic Forecast
77
Table: Population Headline Indicators (Ireland 1990-2025)
78
Table: Key Population Ratios (Ireland 1990-2025)
78
Table: Urban/Rural Population & Life Expectancy (Ireland 1990-2025)
79
Table: Population By Age Group (Ireland 1990-2025)
79
Table: Population By Age Group % (Ireland 1990-2025)
80
Glossary
82
Methodology
84
Pharmaceutical Expenditure Forecast Model
84
Healthcare Expenditure Forecast Model
84
Notes On Methodology
85
Risk/Reward Index Methodology
86
Index Overview
87
Table: Pharmaceutical Risk/Reward Index Indicators
87
Indicator Weightings
88

The Ireland Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Ireland Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Ireland pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Ireland, to test other views - a key input for successful budgeting and strategic business planning in the Irish pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Irish pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Ireland.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%